Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
but you're asking about QR, which based on past QR this company is doing no good, if compared with similar industry, DPharma seems to be a better choice
most of the government hospital medical supplies and distribution channel is through this company. Also the donations from GLIC and GLC for Covid 19 also channel throughout this company. Covid 19 booming up cases in Indonesia might helps their subsidiaries company as well.
They monopolies the gomen hospital contract, that's why margin so poor but revenues are stable despite mco/covid(other pharma at private hospital demands will decrease because medical tourism and non urgent cases drop). Logistic and distribution other pharmas cannot compete. Their indo bussiness is starting to show some growth and the phis system that keep dragging their profit is now gone. IMO this pharma have the most potential
no worries about pharma, they not operate for msia only, they have enough contract to gain the income from indonesia. While vaccine come out, there is no more goreng, its profit gain.
